Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients.

[1]  S. Miura,et al.  Rosuvastatin Activates ATP-Binding Cassette Transporter A1–Dependent Efflux Ex Vivo and Promotes Reverse Cholesterol Transport in Macrophage Cells in Mice Fed a High-Fat Diet , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[2]  M. Phillips.  Molecular Mechanisms of Cellular Cholesterol Efflux* , 2014, The Journal of Biological Chemistry.

[3]  R. Dullaart,et al.  Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes , 2014, European journal of clinical investigation.

[4]  M. Malloy,et al.  Prebeta-1 HDL and coronary heart disease , 2012, Current opinion in lipidology.

[5]  Zahi A Fayad,et al.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.

[6]  J. Albers,et al.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. , 2012, Biochimica et biophysica acta.

[7]  A. van Tol,et al.  Carotid intima media thickness is related positively to plasma pre ß-high density lipoproteins in non-diabetic subjects. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[8]  C. Town,et al.  Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy , 2011, Circulation.

[9]  Christian Zellner,et al.  Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. , 2011, The American journal of cardiology.

[10]  Børge G Nordestgaard,et al.  High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. , 2010, Clinical chemistry.

[11]  S. Carson,et al.  Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 , 2009 .

[12]  G. Dallinga-Thie,et al.  Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. , 2009, Biochimica et biophysica acta.

[13]  John S. Hill,et al.  Atorvastatin Inhibits ABCA1 Expression and Cholesterol Efflux in THP-1 Macrophages by an LXR-dependent Pathway , 2008, Journal of cardiovascular pharmacology.

[14]  S. Ishibashi,et al.  Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. , 2008, Journal of atherosclerosis and thrombosis.

[15]  D. Rader,et al.  Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. , 2007, The Journal of clinical investigation.

[16]  E. Schaefer,et al.  Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. , 2007, The American journal of cardiology.

[17]  Andrew J. Brown,et al.  SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. , 2006, The Biochemical journal.

[18]  E. Favari,et al.  Relative Contributions of ABCA1 and SR-BI to Cholesterol Efflux to Serum From Fibroblasts and Macrophages , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Serkalem Demissie,et al.  Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[20]  C. Argmann,et al.  Regulation of Macrophage Cholesterol Efflux through Hydroxymethylglutaryl-CoA Reductase Inhibition , 2005, Journal of Biological Chemistry.

[21]  A. Groen,et al.  Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment , 2005, Diabetologia.

[22]  T. Egashira,et al.  Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men. , 2004, Clinical chemistry.

[23]  P. Duchateau,et al.  Measurement of prebeta-1 HDL in human plasma by an ultrafiltration-isotope dilution technique. , 1997, Analytical biochemistry.

[24]  T. Miida,et al.  Pre beta 1-high-density lipoprotein increases in coronary artery disease. , 1996, Clinical chemistry.

[25]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[26]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[27]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[28]  C. Fielding,et al.  Prebeta-migrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. , 1987, Journal of lipid research.

[29]  I. Gelissen,et al.  The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. , 2008, Atherosclerosis.

[30]  A. Tall.  Plasma lipid transfer proteins. , 1995, Annual Review of Biochemistry.

[31]  S. Giunta,et al.  Immunofixation electrophoresis (IFE) of serum apolipoproteins: a new tool for probing lipoprotein disorders and the atherosclerosis risk. , 1992, Archives of gerontology and geriatrics.